A Novel Augmented Reality System (ARssist & ARport) for the Assistant Surgeon in Robotic Assisted Surgery:
A Novel Augmented Reality System (ARssist & ARport) for the Assistant Surgeon in Robotic Assisted Surgery: A Pilot Study
Robotic prostatectomy is a surgery for treating localized prostate cancer. The ARssist & ARport system is a novel augmented reality system designed for the assistant surgeon, allowing delivery of augmented reality information. This study aims at evaluating the safety and feasibility of the use of ARssist & ARport system in robotic prostatectomy.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This is a prospective study to evaluate the clinical feasibility and safety of the ARssist and ARport system during robotic surgery with Robotic surgical System. During the operation, the assistant surgeon will utilize the ARssist & ARport system to assist the chief surgeon. Subjects will receive standard post-operative care. The primary objective of this study is to demonstrate the safety and clinical feasibility of the ARssist and ARport system in helping the patient side surgeon perform laparoscopic tasks during robotic assisted urological surgeries, with primary endpoints being safety data and complications.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Yuen Chun Jeremy TEOH, MD
- Phone Number: 35053933
- Email: jeremyteoh@surgery.cuhk.edu.hk
Study Contact Backup
- Name: Ho Ming Chiris WONG, MBChB
Study Locations
-
-
-
Hong Kong, Hong Kong
- Recruiting
- Prince of Wales Hospital
-
Contact:
- Jeremy Yuen-Chun TEOH, FRCS(Ed)
- Phone Number: 35052625
- Email: jeremyteoh@surgery.cuhk.edu.hk
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Patient Inclusion Criteria
- Age >18 years
- Body mass index <35kg/m2
- Suitable for minimally invasive surgery
- Willingness to participate as demonstrated by giving informed consent
- Clinically diagnosed with urological conditions that are indicated for robotic assisted radical prostatectomy with or without lymph node dissection
Patient Exclusion Criteria
- Contraindication to general anaesthesia
- Severe concomitant illness that drastically shortens life expectancy or increases risk of therapeutic intervention
- Untreated active infection
- Uncorrectable coagulopathy
- Presence of another malignancy or distant metastasis
- Emergency surgery
- Vulnerable population (e.g. mentally incapacitated persons)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: ARssist & ARport System
|
The surgery will follow the same steps of a standard robotic assisted radical prostatectomy procedure, with the addition of the ARssist and/or ARport system used by the patient side surgeon. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of intervention-related surgical complication
Time Frame: On Day 30
|
All post-operative complications within 30 days. Complications will be classified based on the Clavien-Dindo classification of surgical complications |
On Day 30
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Performance of the patient side surgeon
Time Frame: Perioperative
|
By Global Operative Assessment of Laparoscopic Skills( GOALS) checklist, a 5-item global rating scale scored on a 5-point scale, the higher mark reflect the better performance |
Perioperative
|
|
Specific feedback on the use of the system by patient side surgeon
Time Frame: Perioperative
|
A customized questionnaire of 10 items on a 5-point Likert scale ; the items included are selected and adopted from the feedback questionnaire designed for a study on HoloLens use in ureteroscopic procedure; by a System Usability Scale; the NASA Task Load Index and the Simulator sickness questionnaire. The higher the marks reflect the better performance |
Perioperative
|
|
Operative Time
Time Frame: Perioperative
|
The duration of operation |
Perioperative
|
|
Blood Loss
Time Frame: Perioperative
|
The total amount of blood loss in the operation in ml |
Perioperative
|
|
Hospital Stay
Time Frame: Perioperative
|
Duration of hospital stay in days |
Perioperative
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Yuen Chun Jeremy TEOH, MD, Chinese University of Hong Kong
Publications and helpful links
General Publications
- Sgarbura O, Vasilescu C. The decisive role of the patient-side surgeon in robotic surgery. Surg Endosc. 2010 Dec;24(12):3149-55. doi: 10.1007/s00464-010-1108-9. Epub 2010 May 22.
- Al Janabi HF, Aydin A, Palaneer S, Macchione N, Al-Jabir A, Khan MS, Dasgupta P, Ahmed K. Effectiveness of the HoloLens mixed-reality headset in minimally invasive surgery: a simulation-based feasibility study. Surg Endosc. 2020 Mar;34(3):1143-1149. doi: 10.1007/s00464-019-06862-3. Epub 2019 Jun 18.
- Qian L, Deguet A, Kazanzides P. ARssist: augmented reality on a head-mounted display for the first assistant in robotic surgery. Healthc Technol Lett. 2018 Sep 17;5(5):194-200. doi: 10.1049/htl.2018.5065. eCollection 2018 Oct.
- McCulloch P, Altman DG, Campbell WB, Flum DR, Glasziou P, Marshall JC, Nicholl J; Balliol Collaboration; Aronson JK, Barkun JS, Blazeby JM, Boutron IC, Campbell WB, Clavien PA, Cook JA, Ergina PL, Feldman LS, Flum DR, Maddern GJ, Nicholl J, Reeves BC, Seiler CM, Strasberg SM, Meakins JL, Ashby D, Black N, Bunker J, Burton M, Campbell M, Chalkidou K, Chalmers I, de Leval M, Deeks J, Ergina PL, Grant A, Gray M, Greenhalgh R, Jenicek M, Kehoe S, Lilford R, Littlejohns P, Loke Y, Madhock R, McPherson K, Meakins J, Rothwell P, Summerskill B, Taggart D, Tekkis P, Thompson M, Treasure T, Trohler U, Vandenbroucke J. No surgical innovation without evaluation: the IDEAL recommendations. Lancet. 2009 Sep 26;374(9695):1105-12. doi: 10.1016/S0140-6736(09)61116-8.
- Barkun JS, Aronson JK, Feldman LS, Maddern GJ, Strasberg SM; Balliol Collaboration; Altman DG, Barkun JS, Blazeby JM, Boutron IC, Campbell WB, Clavien PA, Cook JA, Ergina PL, Flum DR, Glasziou P, Marshall JC, McCulloch P, Nicholl J, Reeves BC, Seiler CM, Meakins JL, Ashby D, Black N, Bunker J, Burton M, Campbell M, Chalkidou K, Chalmers I, de Leval M, Deeks J, Grant A, Gray M, Greenhalgh R, Jenicek M, Kehoe S, Lilford R, Littlejohns P, Loke Y, Madhock R, McPherson K, Rothwell P, Summerskill B, Taggart D, Tekkis P, Thompson M, Treasure T, Trohler U, Vandenbroucke J. Evaluation and stages of surgical innovations. Lancet. 2009 Sep 26;374(9695):1089-96. doi: 10.1016/S0140-6736(09)61083-7.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CRE 2025.896
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.